GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » Price-to-Owner-Earnings

Echo Therapeutics (Echo Therapeutics) Price-to-Owner-Earnings : (As of Apr. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics Price-to-Owner-Earnings?

As of today (2024-04-26), Echo Therapeutics's share price is $0.0002. Echo Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Echo Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ECTE's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.79
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-26), Echo Therapeutics's share price is $0.0002. Echo Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2016 was $-1.28. Therefore, Echo Therapeutics's PE Ratio for today is At Loss.

As of today (2024-04-26), Echo Therapeutics's share price is $0.0002. Echo Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.28. Therefore, Echo Therapeutics's PE Ratio without NRI for today is At Loss.


Echo Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Echo Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics Price-to-Owner-Earnings Chart

Echo Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Echo Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Echo Therapeutics's Price-to-Owner-Earnings

For the Medical Devices subindustry, Echo Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Echo Therapeutics's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Echo Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Echo Therapeutics's Price-to-Owner-Earnings falls into.



Echo Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Echo Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0002/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Echo Therapeutics  (OTCPK:ECTE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Echo Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Echo Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Echo Therapeutics (Echo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830
Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.
Executives
Michael M Goldberg director C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman 10 percent owner 230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp 10 percent owner 250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p. 10 percent owner 152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright director ONE CORPORATE CENTER, RYE NY 10580
William Grieco director 830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman director, officer: EXEC. CHAIRMAN AND INTERIM CEO C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney director, officer: CEO AND PRESIDENT C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker officer: CFO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines